The initial success of Sildenafil undeniably reshaped the medication landscape, but investing in companies primarily reliant on off-patent versions presents a uncertain picture. Despite early returns were significant, the expiration of patents and the appearance of less expensive alternatives have diminished market share. Consequently, a thorough e